TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy

Human Gene Therapy

Volumn 21, Issue 8, 2010, Pages 929-941

  Preuß, Ellen ^a,b   Treschow, Alexandra ^c   Newrzela, Sebastian ^b,c   Brücher, Daniela ^b   Weber, Kristoffer ^a   Felldin, Ulrika ^c   Alici, Evren ^c   Gahrton, Gösta ^c   Von Laer, Dorothee ^b,d   Dilber, M Sirac ^c   Fehse, Boris ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Frankfurter Stiftung für Krebskranke Kinder   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; RETROVIRUS VECTOR; TK.007; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CODON; CONTROLLED STUDY; DISEASE SEVERITY; GENE; GENE EXPRESSION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HSVTK GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OBSERVATION; PRIMARY IMMUNE RESPONSE; SUICIDE GENE THERAPY; T LYMPHOCYTE;

ANIMALS; CELL LINE; CODON; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; RETROVIRIDAE; T-LYMPHOCYTES; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

MURINAE; SIMPLEXVIRUS;

EID: 77955484494     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.042     Document Type: Article

References (49)

1. Alizadeh, M., Bernard, M., Danic, B., Dauriac, C., Birebent, B., Lapart, C., Lamy, T., le Prise, P.Y., Beauplet, A., Bories, D., Semana, G., and Quelvennec, E. (2002). Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99, 4618-4625
2. al-Shawi, R., Burke, J., Wallace, H., Jones, C., Harrison, S., Buxton, D., Maley, S., Chandley, A., and Bishop, J.O. (1991). The herpes simplex virus type 1 thymidine kinase is expressed in the testes of transgenic mice under the control of a cryptic promoter. Mol. Cell. Biol. 11, 4207-4216.
3. Balzarini, J., Liekens, S., Solaroli, N., el Omari, K., Stammers, D.K., and Karlsson, A. (2006). Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimi-dine to purine nucleoside phosphorylation. J. Biol. Chem. 281, 19273-19279.
4. Baum, C., and Fehse, B. (2003). Mutagenesis by retroviral transgene insertion: Risk assessment and potential alternatives. Curr. Opin. Mol. Ther. 5, 458-462.
5. Baum, C., Hegewisch-Becker, S., Eckert, H.G., Stocking, C., and Ostertag, W. (1995). Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69, 7541-7547.
6. Biron, K.K. (2006). Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154-163.
7. Black, M.E., Kokoris, M.S., and Sabo, P. (2001). Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61, 3022-3026.
8. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., and Bordignon, C. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724.
9. Bonini, C., Bondanza, A., Perna, S.K., Kaneko, S., Traversari, C., Ciceri, F., and Bordignon, C. (2007). The suicide gene therapy challenge: How to improve a successful gene therapy approach. Mol. Ther. 15, 1248-1252.
10. Burt, R.K., Drobyski, W.R., Seregina, T., Traynor, A., Oyama, Y., Keever-Taylor, C., Stefka, J., Kuzel, T.M., Brush, M., Ro-driquez, J., Burns, W., Tennant, L., and Link, C. (2003). Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp. Hematol. 31, 903-910.
11. Chalmers, D., Ferrand, C., Apperley, J.F., Melo, J.V., Ebeling, S., Newton, I., Duperrier, A., Hagenbeek, A., Garrett, E., Tiber-ghien, P., and Garin, M. (2001). Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol. Ther. 4, 146-148.
12. Deschamps, M., Mercier-Lethondal, P., Certoux, J.M., Henry, C., Lioure, B., Pagneux, C., Cahn, J.Y., Deconinck, E., Robinet, E., Tiberghien, P., and Ferrand, C. (2007). Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 110, 3842-3852.
13. Dilber, M.S., Abedi, M.R., Christensson, B., Bjorkstrand, B., Kidder, G.M., Naus, C.C., Gahrton, G., and Smith, C.I. (1997). Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57, 1523-1528.
14. Fehse, B., Richters, A., Putimtseva-Scharf, K., Klump, H., Li, Z., Ostertag, W., Zander, A.R., and Baum, C. (2000). CD34 splice variant: An attractive marker for selection of gene-modified cells. Mol. Ther. 1, 448-456.
15. Fehse, B., Kustikova, O.S., Li, Z., Wahlers, A., Bohn, W., Beyer, W.R., Chalmers, D., Tiberghien, P., Kuhlcke, K., Zander, A.R., and Baum, C. (2002). A novel "sort-suicide" fusion gene vector for T cell manipulation. Gene Ther. 9, 1633-1638.
16. \+-enriched blood stem cells. Blood 104, 3408-3409.
17. Fehse, B., Kustikova, O.S., Bubenheim, M., and Baum, C. (2004b). Pois(s)on\it's a question of dose.. Gene Ther. 11, 879-881.
18. Fillat, C., Carrio, M., Cascante, A., and Sangro, B. (2003). Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr. Gene Ther. 3, 13-26.
19. Garin, M.I., Garrett, E., Tiberghien, P., Apperley, J.F., Chalmers, D., Melo, J.V., and Ferrand, C. (2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97, 122-129.
20. Hildinger, M., Abel, K.L., Ostertag, W., and Baum, C. (1999). Design of 5 untranslated sequences in retroviral vectors developed for medical use. J. Virol. 73, 4083-4089.
21. Introna, M., Barbui, A.M., Bambacioni, F., Casati, C., Gaipa, G., Borleri, G., Bernasconi, S., Barbui, T., Golay, J., Biondi, A., and Rambaldi, A. (2000). Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11, 611-620.
22. Kokoris, M.S., and Black, M.E. (2002). Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 11, 2267-2272.
23. Kröger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Born-hä user, M., Reiter, A., Zabelina, T., Zander, A.R., and Fehse, B. (2007). Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 1109, 1316-1321.
24. Kustikova, O.S., Wahlers, A., Kuhlcke, K., Stahle, B., Zander, A.R., Baum, C., and Fehse, B. (2003). Dose finding with ret-roviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102, 3934-3937.
25. Lemoine, F.M., Mesel-Lemoine, M., Cherai, M., Gallot, G., Vie, H., Leclercq, V., Trebeden-Negre, H., Mammes, O., Boyer, O., Noguiez-Hellin, P., and Klatzmann, D. (2004). Efficient transduction and selection of human T-lymphocytes with bi-cistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line. J. Gene Med. 6, 374-386.
26. Li, Z., Schwieger, M., Lange, C., Kraunus, J., Sun, H., van den Akker, E., Modlich, U., Serinsoz, E., Will, E., von Laer, D., Stocking, C., Fehse, B., Schiedlmeier, B., and Baum, C. (2003). Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp. Hematol. 31, 1206-1214.
27. Lizee, G., Aerts, J.L., Gonzales, M.I., Chinnasamy, N., Morgan, R.A., and Topalian, S.L. (2003). Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum. Gene Ther. 14, 497-507.
28. Mercer, K.E., Ahn, C.E., Coke, A., Compadre, C.M., and Drake, R.R. (2002). Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies. Protein Eng. 15, 903-911.
29. Moolten, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
30. phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. 16, 111-118.
31. Munir, K.M., French, D.C., Dube, D.K., and Loeb, L.A. (1994). Herpes thymidine kinase mutants with altered catalytic efficiencies obtained by random sequence selection. Protein Eng. 7, 83-89.
32. Muul, L.M., and Candotti, F. (2007). Immune responses to gene-modified T cells. Curr. Gene Ther. 7, 361-368.
33. Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M.H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.L., Fehse, B., and von Laer, D. (2008). Resistance of mature T cells to oncogene transformation. Blood 112, 2278-2286.
34. Ostermann, N., Lavie, A., Padiyar, S., Brundiers, R., Veit, T., Reinstein, J., Goody, R.S., Konrad, M., and Schlichting, I. (2000). Potentiating AZT activation: Structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J. Mol. Biol. 304, 43-53.
35. Pantuck, A.J., Matherly, J., Zisman, A., Nguyen, D., Berger, F., Gambhir, S.S., Black, M.E., Belldegrun, A., and Wu, L. (2002). Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther. 13, 777-789.
36. Portsmouth, D., Hlavaty, J., and Renner, M. (2007). Suicide genes for cancer therapy. Mol. Aspects Med. 28, 4-41.
37. Qasim, W., Thrasher, A.J., Buddle, J., Kinnon, C., Black, M.E., and Gaspar, H.B. (2002). T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Ther. 9, 824-827.
38. Qiao, J., Black, M.E., and Caruso, M. (2000). Enhanced ganci-clovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum. Gene Ther. 11, 1569-1576.
39. Rettig, M.P., Ritchey, J.K., Meyerrose, T.E., Haug, J.S., and Dipersio, J.F. (2003). Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol. Ther. 8, 29-41.
40. Robinet, E., Fehse, B., Ebeling, S., Sauce, D., Ferrand, C., and Tiberghien, P. (2005) Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy 7, 150-157.
41. Salomon, B., Maury, S., Loubiere, L., Caruso, M., Onclercq, R., and Klatzmann, D. (1995). A truncated herpes simplex virus thymidine kinase phosphorylates thymidine and nucleoside analogs and does not cause sterility in transgenic mice. Mol. Cell. Biol. 15, 5322-5328.
42. Sastry, L., Johnson, T., Hobson, M.J., Smucker, B., and Cornetta, K. (2002). Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther. 9, 1155-1162.
43. Schambach, A., Bohne, J., Baum, C., Hermann, F.G., Egerer, L., von Laer, D., and Giroglou, T. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641-645.
44. Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop, H.E., Spencer, D.M., and Rooney, C.M. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247-4254.
45. Thomis, D.C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C., and Clackson, T. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249-1257.
46. Tiberghien, P., Ferrand, C., Lioure, B., Milpied, N., Angonin, R., Deconinck, E., Certoux, J.M., Robinet, E., Saas, P., Petracca, B., Juttner, C., Reynolds, C.W., Longo, D.L., Herve, P., and Cahn, J.Y. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted alloge-neic marrow graft. Blood 97, 63-72.
47. Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.C., Lanzavecchia, A., Manz, M.G. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304, 104-107.
48. Treschow, A., Unger, C., Aints, A., Felldin, U., Aschan, J., and Dilber, M.S. (2007). OuaSelect, a novel ouabain-resistant human marker gene that allows efficient cell selection within 48h. Gene Ther. 14, 1564-1572.
49. Wagner, R., Graf, M., Bieler, K., Wolf, H., Grunwald, T., Foley, P., and Uberla, K. (2000). Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors. Hum. Gene Ther. 11, 2403-2413.